From: A dual-targeting ruthenium nanodrug that inhibits primary tumor growth and lung metastasis via the PARP/ATM pathway
Ksv * 105 (L mol−1)
Kq * 1013 (L mol−1 s−1)
Number of binding sites (n)
Kb * 105 (L mol−1)
2b
1.09
1.89
1.1
3.97